- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05003635
External Vacuum Expansion: Evaluation in Breast Reconstructive Surgery Evaluation in Breast Reconstructive Surgery (EVE)
External Vacuum Expansion: Evaluation in Breast Reconstructive Surgery
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maud Rijkx, MD, MsC
- Phone Number: +31 (0) 43 38 723 08
- Email: maud.rijkx@mumc.nl
Study Locations
-
-
-
Amsterdam, Netherlands
- Recruiting
- Amsterdam University Medical Center (VUMC)
-
Contact:
- Jan Maerten Smit, MD, MsC
-
Hengelo, Netherlands
- Recruiting
- Ziekenhuis Groep Twente (ZGT)
-
Contact:
- Ute Schmidbauer, MD, PhD
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229 HX
- Recruiting
- Maastricht University Medical Center+
-
Contact:
- Andrzej Piatkowski, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female
- Age 23-69
- BMI 18-35 - stable weight, no fluctuations
- Have undergone a total mastectomy at least 3 months prior the study, whether therapeutic or prophylactic, whether unilateral or bilateral, with no resection of the pectoralis muscle
- Agrees to have reconstruction at the time of study involving only autologous fat grafting (AFT)
- Assessed by surgeon to have enough donor fat
- Passes a 20-minutes tolerance test with EVEBRA Device. (Patient will be fitted, instructed on the use, and given the EVEBRA Device to try in the office for 20 minutes. She passes if she tolerates its use, feels comfortable wearing it, and is able to comply with the required wear of the device.)
Exclusion Criteria:
- untreated breast cancer
- history of radiation therapy on the involved breast, even if it was part of a previous breast conservation procedure
- completed chemotherapy course less than 2 months prior (acceptable to still be on aromatase inhibitors)
- except for the biopsy leading to the diagnosis of cancer, had surgery to breast prior to the mastectomy (e.g., multiple biopsies, implant augmentation, mastopexy, fat grating)
- had mastectomy wound healing complications, e.g., seroma, wound breakdown, infection
- mastectomy defect/scar has significant skin excess and deep folds adherent to the chest wall
- has a pacemaker or aneurysm clips
- pregnancy or breastfeeding
- had a cardiac stent placed within the last 2 months
- claustrophobic, as reported by patient
- known current substance abuse, as reported by patient
- history of silicone allergy, as reported by patient
- history of Gadolinium allergy, as reported by patient
- history of lidocaine allergy, as reported by patient
- bleeding diathesis, whether primary or iatrogenic, as reported by patient cigarette smoker and/or Smokeless cigarette smokers, as reported by patient
- medical conditions that preclude breast reconstruction including uncontrolled hypertension or diabetes, renal failure, steroid dependent asthma, and on immuno- suppressant medications, as reported by patient
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: AFT+ EVEBRA device (intervention arm)
Before and after the AFT surgery, patients are required to wear the EVEBRA expansion device for a total duration of 4 weeks. Thereafter patients will receive a PexyBra over the reconstructed breast. Pre-operatively patients are required to wear the device for a total of 200 hours. |
Wear 2 weeks pre-operatively for a total duration of 200 hours.
Wear 2 weeks post-operatively for 10 hours a day.
|
No Intervention: AFT without EVEBRA device (control arm)
Patients will receive the AFT treatment for total reconstruction without the requirement of wearing the EVEBRA device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness measured in volume (MRI)
Time Frame: 1 year
|
All women will have an MRI for Baseline Breast Volume measurement at the time of enrollment. Final breast volume will be also determined by MRI 6 months after the first grafting procedure (AFT#1). The primary effectiveness endpoint is the Percentage Augmentation of the mastectomy defect at 12 months after AFT#1. |
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The quality of the reconstructed breast tissue as determined by MRI.
Time Frame: 12 months
|
Presence + description of necrotic cysts (Scale: amount of cyst and size in centimeters)
|
12 months
|
The patient reported satisfaction at baseline and post-AFT using the Breast-Q Questionnaire
Time Frame: 12 months
|
Qscore will be used to assess final scores.
As described in the BREAST-Q Module, summed scores will be converted into a score from 0 (worst) to 100 (best) per domain.
Higher scores reflect a better outcome.
|
12 months
|
Return of sensation to the breast as determined by Semmes-Weinstein monofilaments (map of the reconstructed breast mound with record of sensory levels)
Time Frame: 12 months
|
12 months
|
|
Visual/standard photographic appearance of the reconstructed breast will be determined using a Likert scale 1-5.
Time Frame: 12 months
|
The aesthetic improvement will be rated using pre-operative and one year post-operative 2D images by a group of experts, breast cancer patients and age-matched male and female laymen.
All parties rate the pre-/post- 3D images on a Likert scale (5 points) with one indicating no improvement and 5 indicating perfect improvement.
|
12 months
|
Difference in chest circumference between the peak of the reconstructed breast mound and the circumference just below the inframammary line
Time Frame: 12 months
|
Difference noted in centimeters (cm)
|
12 months
|
Difference in bra cup size
Time Frame: 12 months
|
Cup size before and after reconstruction will be noted .
|
12 months
|
Difference in Breast Volume from the randomization baseline after the three sessions of fat grafting (Final Reconstructed Breast Volumes) as measured by the validated Vectra 3D imaging system and the MRI.
Time Frame: 12 months
|
Volume change will be noted in cubic centimetre(cc)
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andrzej Piatkowski de Gryzmala, MD, MsC, Maastricht University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- METC20-099
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Institut fuer FrauengesundheitSamsung Bioepis Co., Ltd.RecruitingBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer FemaleGermany
-
Wake Forest University Health SciencesAtrium Health NavicentActive, not recruitingBreast Cancer Female | Early-stage Breast CancerUnited States
Clinical Trials on EVEBRA device
-
Facet TechnologiesLifeScanCompletedDiabetesUnited States
-
AOTI Ltd.UnknownDiabetic Foot UlcerUnited Kingdom, United States, Germany, France, Luxembourg
-
Karolinska InstitutetUnknownDegenerative Disc Disease | Discogenic Low Back PainSweden
-
Cala Health, Inc.Not yet recruiting
-
International Agency for Research on CancerUniversity of North Carolina Global Project Zambia; Liger Medical LlcCompleted
-
Universitair Ziekenhuis BrusselTerminated
-
Massachusetts General HospitalCase Western Reserve UniversityRecruitingSurgery--ComplicationsUnited States
-
University of BernDCB Research AG; Insel Gruppe AG, University Hospital BernActive, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseSwitzerland
-
NYU Langone HealthCompleted
-
Kasey PhiferThe National Centre for ElectroMagnetic Therapies CICCompletedUnspecified Trauma- and Stressor-Related DisorderUnited Kingdom